About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The group of Clinical Neuroimmunology - Centre d'Esclerosi Múltiple de Catalunya (Cemcat) at the Vall d'Hebron Institut de Recerca (VHIR) is a multidisciplinary group dedicated to clinical assistance, physical and cognitive rehabilitation, and clinical and basic research on multiple sclerosis (MS). Cemcat is a national but also an international reference center in the clinical assistance of MS patients. The research performed in the group is divided and further combined in clinical and basic research. In addition, basic research has a marked translational character since the ultimate goal of the group is to improve the quality of life of patients suffering from MS, through in-depth knowledge of the pathogenic mechanisms of the disease and the development of new and more effective therapeutic approaches.
PMID: 35727945 Journal: BRAIN Year: 2022 Reference: Brain. 2022 Jun 21. pii: 6612696. doi: 10.1093/brain/awac220. Impact factor: 13.501 Publication type: Paper in international publication Authors: Rodriguez-Acevedo, Breogan, Ruiz-Ortiz, Mariano, Salerno, Annalaura, Tagliani, Paula, Tur, Carmen, Vidal-Jordana, Angela, Zabalza, Ana, Sastre-Garriga, Jaume, Rovira, Alex, Comabella, Manuel et al. DOI: 10.1093/brain/awac220
PMID: 35703428 Journal: ANNALS OF NEUROLOGY Year: 2022 Reference: Ann Neurol. 2022 Jun 15. doi: 10.1002/ana.26440. Impact factor: 10.422 Publication type: Paper in international publication Authors: Brandt, Alexander U, Smith, Terry J, Yeaman, Michael R, Green, Ari J, Llufriu, Sara, Pittock, Sean, Flanagan, Eoin P, Bhatti, M Tariq, Rommer, Paulus S, Bsteh, Gabriel et al. DOI: 10.1002/ana.26440
PMID: 35685944 Journal: Frontiers in Neuroinformatics Year: 2022 Reference: Front Neuroinform. 2022 May 23;16:769274. doi: 10.3389/fninf.2022.769274. eCollection 2022. Impact factor: 4.081 Publication type: Paper in international publication Authors: Simeon, Guillem, Piella, Gemma, Camara, Oscar, Pareto, Deborah et al. DOI: 10.3389/fninf.2022.769274
PMID: 35672562 Journal: Translational Stroke Research Year: 2022 Reference: Transl Stroke Res. 2022 Jun 8. pii: 10.1007/s12975-022-01044-1. doi: 10.1007/s12975-022-01044-1. Impact factor: 6.829 Publication type: Paper in international publication Authors: Tomasello, Alejandro, Ribo, Marc, Gil, Alberto, Li, Jiahui, Esteves, Marielle, Coscojuela, Pilar, de Dios, Marta, Pinana, Carlos, Requena, Manuel, Gragmegna, Laura Ludovica et al. DOI: 10.1007/s12975-022-01044-1
PMID: 32469284 Journal: JOURNAL OF PALLIATIVE MEDICINE Year: 2020 Reference: J Palliat Med. 2020 Nov;23(11):1426-1443. doi: 10.1089/jpm.2020.0220. Epub 2020 May 29. Impact factor: 2.085 Publication type: Paper in international publication Authors: Rahn, Anne C, Kleiter, Ingo, Aleksovska, Katina, Battaglia, Mario A, Bay, Jette, Copetti, Massimiliano, Drulovic, Jelena, Kooij, Liesbeth, Mens, John, Meza Murillo, Edwin R et al. DOI: 10.1089/jpm.2020.0220
PMID: 32439639 Journal: AMERICAN JOURNAL OF NEURORADIOLOGY Year: 2020 Reference: AJNR Am J Neuroradiol. 2020 Jun;41(6):1001-1008. doi: 10.3174/ajnr.A6547. Epub 2020 May 21. Impact factor: 3.381 Publication type: Paper in international publication Authors: Tintore, M, Sastre-Garriga, J, Auger, C, Montalban, X, Evangelou, N, Rovira, A, Cappelle, S, Crescenzo, F, Alberich, M, Arrambide, G et al. DOI: 10.3174/ajnr.A6547
PMID: 32436209 Journal: REVISTA DE NEUROLOGIA Year: 2020 Reference: Rev Neurol. 2020 Jun 1;70(11):417-429. doi: 10.33588/rn.7011.2020122. Impact factor: 0.562 Publication type: Review in international publication Authors: Arroyo, R, Brieva, Ll, Calles-Hernandez, M C, Carrascal, P, Comabella, M, Costa-Frossard, L, Eichau, S, Garcia-Merino, J A, Ginestal, R, Gonzalez, I et al. DOI: 10.33588/rn.7011.2020122
PMID: 32404034 Journal: STROKE Year: 2020 Reference: Stroke. 2020 Jun;51(6):1736-1742. doi: 10.1161/STROKEAHA.120.029212. Epub 2020 May 14. Impact factor: 7.19 Publication type: Paper in international publication Authors: Rubiera, Marta, Garcia-Tornel, Alvaro, Olive-Gadea, Marta, Campos, Daniel, Requena, Manuel, Vert, Carla, Pagola, Jorge, Rodriguez-Luna, David, Muchada, Marian, Boned, Sandra et al. DOI: 10.1161/STROKEAHA.120.029212
In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.
Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.
The research findings propose to modify the McDonald 2017 criteria, only in those in whom diagnosis using the current criteria is not possible.
Simoa HD1 equipment
We are looking for 100 healthy volunteers aged 18 or over to participate in a project where the usefulness of biomarkers in serum will be evaluated to predict the prognosis of the disease and the response to treatments.
